An electrographic AV optimization for the maximum integrative atrioventricular and ventricular resynchronization in CRT

JIE LI
Sun Yat-sen University First Affiliated Hospital  https://orcid.org/0000-0002-6889-7091

Yuegang Wang
First Military Medical University Nanfang Hospital: Southern Medical University Nanfang Hospital

Jingting Mai
Sun Yat-Sen University 2nd Affiliated Hospital: Sun Yat-Sen Memorial Hospital

Shilan Chen
SYSU: Sun Yat-Sen University

Menghui Liu
SYSU: Sun Yat-Sen University

Chen Su
SYSU: Sun Yat-Sen University

Xumiao Chen
SYSU: Sun Yat-Sen University

Huiling Huang
SYSU: Sun Yat-Sen University

Yuedong Ma
SYSU: Sun Yat-Sen University

Chong Feng
SYSU: Sun Yat-Sen University

Jingzhou Jiang
SYSU: Sun Yat-Sen University

Jun Liu
SYSU: Sun Yat-Sen University

Jiangui He
SYSU: Sun Yat-Sen University

Anli Tang
SYSU: Sun Yat-Sen University

Yugang Dong
SYSU: Sun Yat-Sen University

Xiaobo Huang
Keywords: AV delay, atrioventricular synchrony, ventricular synchrony, cardiac resynchronization therapy
Abstract

Background:

Atrioventricular (AV) delay could affect AV and ventricular synchrony in cardiac resynchronization therapy (CRT). Strategies to optimize AV delay according to optimal AV synchrony (AV_{opt-AV}) or ventricular synchrony (AV_{opt-V}) would potentially be in discordant. This study aimed to explore a new AV delay optimization algorithm guided by electrograms to get the maximum integrative effects of AV and ventricular resynchronization (opt-AV).

Methods:

Forty-nine patients with CRT were enrolled. AV_{opt-AV} was measured through the Ritter method. AV_{opt-V} was obtained by yielding the narrowest QRS. The opt-AV was considered to be AV_{opt-AV} or AV_{opt-V} when their difference was <20ms, and to be the AV delay with the maximal aortic velocity-time integral between AV_{opt-AV} and AV_{opt-V} when their difference was >20ms.

Results:

The results showed sensing/pacing AV_{opt-AV} (SAV_{opt-AV}/PAV_{opt-AV}) were correlated with atrial activation time (P_{end-As}/P_{end-Ap}) (P<0.05). Sensing/pacing AV_{opt-V} (SAV_{opt-V}/PAV_{opt-V}) were correlated with the intrinsic AV conduction time (As-Vs/Ap-Vs) (P<0.01). The percentages of patients with more than 20ms differences between SAV_{opt-AV}/PAV_{opt-AV} and SAV_{opt-V}/PAV_{opt-V} were 62.9% and 57.1%, respectively. Among them, the opt-AV were linearly correlated with SAV_{opt-AV}/PAV_{opt-AV} and SAV_{opt-V}/PAV_{opt-V}. The sensing opt-AV (opt-SAV)=0.1×SAV_{opt-AV}+0.4×SAV_{opt-V}+70ms (R^2=0.665, P<0.01) and the pacing opt-AV (opt-PAV)=0.25×PAV_{opt-AV}+0.5×PAV_{opt-V}+30ms (R^2=0.560, P<0.01).

Conclusion:

The SAV_{opt-AV}/PAV_{opt-AV} and SAV_{opt-V}/PAV_{opt-V} were correlated with the atrial activation time and the intrinsic AV conduction interval respectively. Almost half of patients had a >20ms difference between SAV_{opt-AV}/PAV_{opt-AV} and SAV_{opt-V}/PAV_{opt-V}. The opt-AV could be estimated based on electrogram parameters.

Background

Cardiac resynchronization therapy (CRT) is a milestone therapy in advanced congestive heart failure for its ability in decreasing symptoms, improving quality of life and exercise capacity, and reducing hospitalization and mortality in selected patients with heart failure \(^1,2\). However, up to 30% – 45% of patients do not respond to CRT therapy \(^1,3\). Among them, almost 50% cases have suboptimal atrioventricular (AV) timing\(^4\).
The AV interval can affect AV and ventricular synchrony simultaneously. However, improving AV and ventricular dyssynchrony is the underlying therapeutic mechanism of CRT. To obtain the optimal AV synchrony, an AV interval is required to ensure that the left ventricle (LV) only contracts after completion of left atrial (LA) contraction\(^5\). At this time, the optimal AV interval is subject to the atrial activation time. If there is inter/intra-atrial conduction delay, a relatively long AV interval is required for delayed LA contraction. Furthermore, ventricular resynchronization is maximally achieved through the narrowest QRS, which is obtained by optimal fusion between intrinsic atrioventricular activation and paced activation\(^6,7\). Therefore, the optimal AV interval should coincide with the intrinsic AV conduction interval for obtaining optimal ventricular synchrony.

As a result, in some cases, the optimal AV delay for maintaining AV synchrony may be quite different from that for maintaining ventricular synchrony. For example, in patients with a long PR interval but normal atrial conduction, optimal ventricular resynchronization (the narrowest QRS) would require a longer AV delay, while this might lead to sub-optimal AV resynchronization since a normal atrial conduction required a relatively short AV delay.

In this study, the AV intervals were optimized according to optimal AV synchrony (AV\(_{\text{opt-AV}}\)) and optimal ventricular synchrony (AV\(_{\text{opt-V}}\)). The relationships between AV\(_{\text{opt-AV}}\) and the atrial activation time, AV\(_{\text{opt-V}}\) and the intrinsic AV interval, AV\(_{\text{opt-AV}}\) and AV\(_{\text{opt-V}}\) were further investigated. The aim was to study the difference between AV\(_{\text{opt-AV}}\) and AV\(_{\text{opt-V}}\), and propose a novel AV optimized algorithm only guided by the intrinsic AV interval and atrial activation time to obtain the maximal integrative effects of AV and ventricular resynchronization.

**Methods**

**Study population**

This was a multicenter, nonrandomized study, which enrolled patients aged 18 or older, who had been implanted with CRT defibrillators for at least 1 month with standard criteria (NYHA classes II-IV; ejection fraction \(\leq 35\%\); sinus rhythm; left bundle branch block with QRS \(\geq 130\) ms). Patients were excluded from the study if they had congenital heart diseases, valve repairment or replacement surgeries, atrial tachyarrhythmias or frequent atrial or ventricular ectopy, and second/third degree of AV block. The protocol of the study was approved by the institutional review boards of the participating hospitals, and all patients gave written informed consent.

**Study procedures**

*General data*

Clinical data, such as demographics (age, gender, etc.), etiology, heart failure status before CRT device implantation (NYHA classes, left ventricular end-diastolic diameter, left ventricular end-systolic diameter,
ejection fraction), medications, CRT device data (model number and date of implant), and the location of the right atrium and LV electrodes were collected before the study procedure.

**Electrocardiogram and device electrograms**

The patient’s intrinsic electrocardiogram (ECG) was recorded after the device marker recording showed atrial sensing (As) and ventricular sensing (Vs) by programming the lower rate to 50/40 bpm and sensed AV delay to 300/350 ms. Heart rate, QRS duration, PR interval, the device-recorded intrinsic AV conduction interval (As-Vs), and atrial activation time (duration from As to the end of the P wave [P_{end-As}]) were sequentially measured. Then the lower rate was programmed to 10 bpm more than the intrinsic heart rate. The intervals from atrial pacing (Ap) to Vs (Ap-Vs), and the duration from Ap to the end of the P wave (P_{end-Ap}) were also measured sequentially for at least 10 times (Fig. 1).

**Measurement of AV delay according to optimal atrioventricular synchrony**

The Ritter method was originally developed for AV delay setting to achieve optimal AV synchrony in patients with complete AV block and preserved LV function. Its aim was to maximize LV filling (including maximizing the role of LA contraction) and minimize pre-systolic mitral regurgitation by ensuring that left ventricular contraction starts soon after the completion of the left atrial contraction. Then it and its analogue became the gold standard for AV delay optimization in CRT. In this study, we used the Ritter method to optimize AV_{opt-AV}. In brief, mitral flow velocity and surface ECG were simultaneously recorded. A short and a long AV delay (AV_{short}/AV_{long}) were programmed, and the relevant intervals from the pacing spike (Q) to the end of the Doppler mitral inflow A wave (QA_{short}/QA_{long}) were measured. AV_{opt-AV} was calculated as follows: AV_{opt-AV} = AV_{long} + QA_{long} − QA_{short}. In this study, the VV intervals were always kept in 0 ms.

**Measurement of AV delay according to optimal ventricular synchrony**

The narrower the QRS duration was, the more synchronous the ventricle was. Simultaneous 12-lead ECGs were recorded when the sensing/pacing AV delays (SAV/PAV) were programmed to values from 70 ms to an AV delay of 40 ms less than the intrinsic As-Vs/Ap-Vs by 10-ms steps in random order. The durations of QRS were automatically calculated by the built-in software in the ECG machine. The SAV/PAV delays with the narrowest QRS duration were considered sensing/pacing AV_{opt-V} (SAV_{opt-V}/PAV_{opt-V}) (Fig. 2).

**Determination of the optimal AV delay**

When sensing/pacing AV_{opt-AV} (SAV_{opt-AV}/PAV_{opt-AV}) with SAV_{opt-V}/PAV_{opt-V} were compared, if the difference in values (D-values) was <20 ms, SAV_{opt-AV}/PAV_{opt-AV} and SAV_{opt-V}/PAV_{opt-V} were regarded as not different, and were considered as the optimal sensing/pacing AV delay (opt-SAV/opt-PAV). If the D-values were ≥20 ms, the aortic velocity-time integral (AoVTI) was measured by continuous wave Doppler recordings from SAV_{opt-AV}/PAV_{opt-AV} to SAV_{opt-V}/PAV_{opt-V} by 10-ms steps. SAV/PAV with the
maximum AoVTI were considered as the opt-SAV/opt-PAV. All measurements of echocardiographic data were averaged from nine to 12 consecutive cardiac beats.

**Statistical analysis**

Continuous variables that were normally distributed are shown as mean ± standard deviation. Non-normally distributed variables are shown as median and interquartile range. The data were analyzed with IBM SPSS software version 20.0 for Windows (IBM Inc., Armonk, NY, USA). The paired-samples t-test or two related-samples Wilcoxon rank sum tests were used in between-group statistical analysis according to evaluation of a normal distribution. Regression analysis and Pearson's correlation coefficient were performed to evaluate correlations. The theoretical frequency $P < 0.05$ was defined as statistically significant.

**Results**

**Patients population**

A total of 49 patients were enrolled in the study from three hospitals (the First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and Nanfang Hospital of Nanfang Medical University) from July 2017 to May 2020. The clinical characteristics of the patients are shown in Table 1. The majority of patients (35/49) were men. The mean intrinsic PR interval and QRS duration were 185.88 ± 38.20 (115–275) ms and 166.29 ± 21.34 (146–237) ms. The atrial electrodes were placed in the right atrial appendage in all patients.
Table 1
Clinical characteristics of the patients involved in the study

|                        | 67.25 ± 9.37 |
|------------------------|--------------|
| **Age, years**         |              |
| Male/female            | 35/14        |
| **Etiology, n (%)**    |              |
| Ischemic heart disease | 20 (40.8)    |
| Dilated cardiomyopathy | 24 (49.0)    |
| Noncompaction of ventricular myocardium | 4 (8.2) |
| Other                  | 1 (2.0)      |
| **NYHA class, n (%)**  |              |
| I                      | 13 (28.9)    |
| II                     | 29 (64.4)    |
| III                    | 4 (8.9)      |
| **Medication, n (%)**  |              |
| Beta-blocker           | 42 (93.3)    |
| ACEI/ARB               | 27 (60.0)    |
| MRA                    | 44 (97.8)    |
| ARNI                   | 18 (40.0)    |
| If-channel inhibitor   | 3 (6.7)      |
| Diuretics              | 4 (8.9)      |
| Digitalis              | 3 (6.7)      |
| UCG                    |              |
| LV EF (%)              | 28.66 ± 4.94 |
| LVEDD (mm)             | 70.42 ± 10.29 |
| LVESD (mm)             | 59.13 ± 10.94 |

NYHA: New York heart association; ACEI: Angiotensin-converting-enzyme inhibitor; ARB: Angiotensin II receptor antagonist; MRA: Aldosterone receptor antagonist; ARNI: Angiotensin receptor-neprilysin inhibitor; If: Funny current; UCG: Ultrasonic cardiogram; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; LVESD: left ventricular end systolic diameter; PA: Pulmonary artery; ECG: Electrocardiogram; As-Vs: Intrinsic atrioventricular conduction time at the time of atrial sensing; Ap-Vs: Intrinsic atrioventricular conduction time at the time of atrial pacing; P_{end−As}: Atrial activation time at the time of atrial sensing; P_{end−Ap}: Atrial activation time at the time of atrial pacing.
| Age, years | 67.25 ± 9.37 |
|-----------|--------------|
| PA pressure (mmHg) | 38.45 ± 6.98 |
| Diastolic mitral regurgitation, n (%) | 31 (68.9) |
| **ECG characteristics** | |
| Intrinsic heart rate (bpm) | 68.21 ± 11.76 |
| PR interval (ms) | 185.88 ± 38.20 |
| QRS duration (ms) | 166.29 ± 21.34 |
| **Location of LV lead, n (%)** | |
| Short axis | |
| Lateral/posterolateral | 32 (65.3) |
| Anterolateral | 13 (25.5) |
| Posterior | 4 (8.2) |
| Anterior | 0 |
| Long axis | |
| Basic | 16 (32.7) |
| Middle | 33 (67.3) |
| Apical | 0 |
| **Device electrogram characteristics** | |
| As-Vs (ms) | 200.02 ± 34.26 |
| Ap-Vs (ms) | 258.33 ± 45.46 |
| P_{end−As} (ms) | 86.08 ± 22.68 |
| P_{end−Ap} (ms) | 136.84 ± 23.92 |

NYHA: New York heart association; ACEI: Angiotensin-converting-enzyme inhibitor; ARB: Angiotensin II receptor antagonist; MRA: Aldosterone receptor antagonist; ARNI: Angiotensin receptor-neprilysin inhibitor; I_{f}: Funny current; UCG: Ultrasonic cardiogram; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; LVESD: left ventricular end systolic diameter; PA: Pulmonary artery; ECG: Electrocardiogram; As-Vs: Intrinsic atrioventricular conduction time at the time of atrial sensing; Ap-Vs: Intrinsic atrioventricular conduction time at the time of atrial pacing; P_{end−As}: Atrial activation time at the time of atrial sensing; P_{end−Ap}: Atrial activation time at the time of atrial pacing.

**Relationship between AV_{opt−AV} and atrial activation time**
AV\textsubscript{opt-AV} was successfully determined in 35 patients by the Ritter method. Regression analysis showed that SAV\textsubscript{opt-AV} was significantly correlated with $P_{\text{end-As}}$ (SAV\textsubscript{opt-AV}=0.80×$P_{\text{end-As}}$+50 ms, $R^2=0.467$, $P<0.01$). A similar result was also found between PAV\textsubscript{opt-AV} and $P_{\text{end-Ap}}$ (PAV\textsubscript{opt-AV}=0.70×$P_{\text{end-Ap}}$+70 ms, $R^2=0.221$, $P<0.05$).

**Relationship between AV\textsubscript{opt-V} and intrinsic AV conduction and QRS duration**

The SAV\textsubscript{opt-V}/PAV\textsubscript{opt-V} was achieved through the narrowest QRS duration in all 49 patients. SAV\textsubscript{opt-V}/PAV\textsubscript{opt-V} were significantly correlated with As-Vs/Ap-Vs (SAV\textsubscript{opt-V}=0.60×As-Vs + 15 ms, $R^2=0.456$, $P<0.01$; PAV\textsubscript{opt-V}=0.60×Ap-Vs + 40 ms, $R^2=0.417$, $P<0.01$), but there was no significant correlation with the intrinsic QRS duration (both $P>0.5$).

**Difference between AV\textsubscript{opt-AV} and AV\textsubscript{opt-V}**

In the 35 patients, in which SAV\textsubscript{opt-AV}/PAV\textsubscript{opt-AV} and SAV\textsubscript{opt-V}/PAV\textsubscript{opt-V} were successfully directly measured simultaneously, no significant correlations were found between SAV\textsubscript{opt-AV} and SAV\textsubscript{opt-V}, and between PAV\textsubscript{opt-AV} and PAV\textsubscript{opt-V} (both $P>0.05$). If >20-ms D-values between SAV\textsubscript{opt-AV}/PAV\textsubscript{opt-AV} and SAV\textsubscript{opt-V}/PAV\textsubscript{opt-V} were considered as meaningful differences, 22/35 (62.9%) patients had a >20-ms difference in SAV and 20/35 (57.1%) had a >20-ms difference in PAV. Among them, 17/35 (48.6%) patients had a >20-ms difference in both SAV and PAV. Moreover, if SAV\textsubscript{opt-AV}/PAV\textsubscript{opt-AV} and SAV\textsubscript{opt-V}/PAV\textsubscript{opt-V} were obtained by calculation according to their relationship with $P_{\text{end-As}}$/$P_{\text{end-Ap}}$ and As-Vs/Ap-Vs, respectively, >20-ms D-values were found in 22/49 (44.9%) patients in SAV, in 29/49 (59.2%) patients in PAV, and in 17/49 (34.7%) patients in both SAV and PAV (Table 2).
Table 2
The percentage of patients with more than 20ms differences between $AV_{opt-AV}$ and $AV_{opt-V}$

| Patients with directly measured AV (n = 35) | Patients with calculated AV* (n = 49) |
|-------------------------------------------|--------------------------------------|
| SAV                                       | 22(62.9%)                            | 22(44.9%)                            |
| PAV                                       | 20(57.1%)                            | 29(59.2%)                            |
| SAV and PAV                               | 17(48.6%)                            | 17(34.7%)                            |

*the Sensing/Pacing $AV_{opt-AV}$ and $AV_{opt-V}$ were calculated according to the following formulae:

- $SAV_{opt-AV} = 0.80 \times P_{end-As} + 50$ ms
- $SAV_{opt-V} = 0.60 \times As-Vs + 15$ ms
- $PAV_{opt-AV} = 0.70 \times P_{end-Ap} + 70$ ms
- $PAV_{opt-V} = 0.60 \times Ap-Vs + 40$ ms

**Relationships of opt-SAV/opt-PAV with $SAV_{opt-AV}/PAV_{opt-AV}$ and $SAV_{opt-V}/PAV_{opt-V}$**

Opt-SAV/opt-PAV was considered according to the maximum AoVTI when the D-values between $SAV_{opt-AV}/PAV_{opt-AV}$ and $SAV_{opt-V}/PAV_{opt-V}$ were > 20 ms. Regression analysis showed that opt-SAV = $0.1 \times SAV_{opt-AV} + 0.4 \times SAV_{opt-V} + 70$ ms ($R^2 = 0.665, P < 0.01$) and that opt-PAV = $0.25 \times PAV_{opt-AV} + 0.5 \times PAV_{opt-V} + 30$ ms ($R^2 = 0.560, P < 0.01$).

**Echocardiographic evaluation of opt-SAV/opt-PAV**

The difference of hemodynamics was evaluated by echocardiographic measurement of AoVTI. In the cases with > 20 ms D-values between $SAV_{opt-AV}$ and $SAV_{opt-V}$, the AoVTI on opt-SAV was significantly greater than the AoVTI on $SAV_{opt-v}$ (opt-SAV - $SAV_{opt-v}$ = $1.52 \pm 0.22$ cm, $P < 0.001$), and was not less than that on $SAV_{opt-AV}$ (opt-SAV - $SAV_{opt-AV}$ = $0.89 \pm 0.82$ cm, $P = 0.290$). Furthermore, the AoVTI on opt-PAV was also significantly greater than that on $PAV_{opt-AV}$ (opt-PAV - $PAV_{opt-AV}$ = $2.47 \pm 0.80$ cm, $P = 0.006$) and $PAV_{opt-V}$ (opt-PAV - $PAV_{opt-V}$ = $0.76 \pm 0.30$ cm, $P = 0.021$), respectively.

**Discussion**

AV delay has effects on both AV and ventricular resynchronization simultaneously in CRT, and could be optimized according to the optimal AV and ventricular synchrony respectively. This study showed that $SAV_{opt-AV}/PAV_{opt-AV}$ were related to the atrial activation time ($P_{end-As}/P_{end-Ap}$), and $SAV_{opt-V}/PAV_{opt-V}$ were related to the intrinsic atrioventricular conduction interval (As-Vs/Ap-Vs). However, nearly 50% of
patients showed a significant difference between $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ and $SAV_{\text{opt-V}}/PAV_{\text{opt-V}}$ ($D$-values > 20 ms). At this time, opt-$SAV$/opt-$PAV$ optimized according to the maximal AoVTI were linearly correlated with $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ and $SAV_{\text{opt-V}}/PAV_{\text{opt-V}}$, and had significantly improved hemodynamics. Therefore, the optimal AV delay in CRT could be considered as $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ or $AV_{\text{opt-V}}/PAV_{\text{opt-V}}$ if the $D$-values were < 20 ms, or it could be achieved by formulas ($opt-SAV = 0.1\times SAV_{\text{opt-AV}}+0.4\times SAV_{\text{opt-V}}+70\text{ ms}$; $opt-PAV = 0.25\times PAV_{\text{opt-AV}}+0.5\times PAV_{\text{opt-V}}+30\text{ ms}$) if the $D$-values were > 20 ms. The AV optimized algorithm with the maximal integrative effects of AV and ventricular resynchronization was shown in Fig. 3.

Optimal atrioventricular synchrony is a mechanical status in which the onset of LV contraction only coincides with the end of LA contraction and yields the longest diastolic filling time and a fully active filling phase. This is also the principle based on the Ritter method and its analogues for optimization of AV delay. Previous studies have shown that this type of AV delay is related to the atrial conduction time. In this study, we defined this AV delay for optimal atrioventricular synchrony as $AV_{\text{opt-AV}}$. Using the duration from As/Ap to the relevant end of the P wave ($P_{\text{end-As}}/P_{\text{end-Ap}}$) as the atrial activation time, the results showed that $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ were linearly correlated with $P_{\text{end-As}}/P_{\text{end-Ap}}$. Similar results were also found by Jones et al. who suggested that $SAV = P_{\text{end-As}}+40\text{ ms}$ and $PAV = P_{\text{end-Ap}}+30\text{ ms}$. We did not find any significant differences when compared these two equations with our formulas (both $P > 0.05$, data not shown).

The duration of QRS is a marker of ventricular synchrony. Many studies have shown that the extent of a decrease in QRS duration is related to clinical improvement and reverse remodeling of the LV in CRT. Achieving the narrowest QRS duration was first applied in VV optimization. This was further used in AV optimization to maximize LV global contractile function because the narrowest QRS duration could be obtained by maximal fusion between intrinsic atrioventricular activation and paced activation. Therefore, AV delay for optimal ventricular synchrony according to the narrowest QRS duration should be correlated with the intrinsic AV conduction interval. In this study, we defined AV delay for the narrowest QRS as $SAV_{\text{opt-V}}/PAV_{\text{opt-V}}$, and found that they were correlated with intrinsic AV conduction (As-Vs/Ap-Vs).

However, in patients with CHF, the intrinsic AV conduction interval and the atrial activation time are not always proportional. In our patients, we could not find a significant correlation between As-Vs/Ap-Vs and $P_{\text{end-As}}/P_{\text{end-Ap}}$ (data not shown). Therefore, AV delay optimized according to maximal AV synchrony, which was correlated with the atrial activation time, did not always coincide with AV delay optimized according to maximal ventricular synchrony, which was correlated with intrinsic AV conduction. In this study, no significant correlations were found between $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ and $SAV_{\text{opt-V}}/PAV_{\text{opt-V}}$, and almost 50% of patients showed > 20-ms differences between $SAV_{\text{opt-AV}}/PAV_{\text{opt-AV}}$ and $SAV_{\text{opt-V}}/PAV_{\text{opt-V}}$. These findings indicated the AV delay optimized only according to optimal AV synchrony or ventricular synchrony was not optimal in approximately half of the patients with CRT.
fact, some studies showed that the narrowest QRS complex in CRT was not always associated with maximal improvement of cardiac contractive function\(^1\). Sometimes the AV delay optimized by the Ritter method is not as useful as other methods (e.g., Doppler-derived AoVTI)\(^2,18,20\). This further indicates that the optimization of AV delay only according to either optimal AV or ventricular synchrony is not sufficient in CRT. Therefore, optimal AV delay with maximal hemodynamic improvement should be the AV interval that produces maximal integration of atrioventricular and ventricular synchrony. In this study, we found that the optimal AV delay with maximal AoVTI was linearly correlated with \(S_{AV_{opt-AV}}/P_{AV_{opt-AV}}\) and \(S_{AV_{opt-V}}/P_{AV_{opt-V}}\) when the D-values between them were > 20ms. The AoVTIs on opt-AV were either significantly greater or not less than that on \(AV_{opt-AV}\) and \(AV_{opt-V}\). Theses indicated that the AV optimization according to the maximal integrative effects of AV and ventricular resynchronization was significantly more effective than the AV interval determined by either optimal AV or ventricular synchrony alone.

There are several limitations to our study. Firstly, we only enrolled 49 patients with CRT. This relatively small number of cases might have affected the accuracy of the regression formula, although the current equation was statistically significant. Secondly, the atrial electrodes were all placed in the right atrial appendages in our patients. The sites of atrial electrodes could affect measurement of the atrial activation time (As-P\(_{end}/Ap-P_{end}\)) and the intrinsic AV conduction time (As-Vs/Ap-Vs). Therefore, the formulas that were used in our study might not be appropriate for other CRT patients whose atrial electrodes placed in different sits. Additionally, we only focused on the optimal AV delay in the condition of biventricular simultaneous pacing but did not study the situation of only LV pacing. However, when or how to select the pacing mode of only LV pacing is still controversial. AV and ventricular synchrony are also required to be considered simultaneously when the AV delay is optimized in only LV pacing mode.

Conclusions

AV delay could affect atrioventricular and ventricular synchrony in CRT. AV delay optimized according to optimal atrioventricular synchrony or optimal ventricular synchrony is correlated with the atrial activation time or the intrinsic AV conduction interval, respectively. However, almost half of the patients show a significant difference between \(AV_{opt-AV}\) and \(AV_{opt-V}\). Optimal AV delay is the maximal integration of atrioventricular and ventricular synchrony, and could be considered as \(S_{AV_{opt-AV}}/P_{AV_{opt-AV}}\) or \(S_{AV_{opt-V}}/P_{AV_{opt-V}}\) if the D-values were < 20 ms, or be obtained by formulas that linearly correlated with \(AV_{opt-AV}\) and \(AV_{opt-V}\) when the D-values were > 20 ms.

Abbreviations

**CRT**
cardiac resynchronization therapy

**SAV**
sensing atrioventricular delay
PAV
pacing atrioventricular delay

\( AV_{\text{opt-AV}} \)
AV delay with optimal atrioventricular synchrony

\( AV_{\text{opt-V}} \)
AV delay optimal ventricular synchrony

opt-AV
the optimal AV delay with the maximum integrative effects of AV and ventricular resynchronization

As
atrial sensing

Ap
atrial pacing

Vs
ventricular sensing

As-Vs
the interval from As to Vs

Ap-Vs
the interval from Ap to Vs

\( P_{\text{end-As}} \)
atrial activation time (duration from As to the end of the P wave)

\( P_{\text{end-Ap}} \)
atrial activation time (duration from Ap to the end of the P wave)

AoVTI
aortic velocity-time integral

**Declarations**

**Ethics approval and consent to participate:** The protocol of the study was approved by Medical Ethics Committee at Sun Yat-Sen University and Nanfang Hospital of Nanfang Medical University, respectively. All patients gave written informed consents.

**Consent for publication:** All authors have reviewed and agree with the content of the article for publication.

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** Not applicable
Authors' contributions: JL, YW, JM and SC were major contributor in the tests on the patients directly. ML and CS corresponded for the statistics of data. XC, HH, YM, CF, JJ, Jun Liu assisted the tests and data collection. JH, AT, YD and XH assisted the design and interpreted the patients. YC and LW corresponded the design and writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements: We thank Ellen Knapp, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

References

[1] Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-49.

[2] Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-50.

[3] Pires LA, Abraham WT, Young JB, Johnson KM. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. AM HEART J 2006; 151:837-43.

[4] Jaffe LM, Morin DP. Cardiac resynchronization therapy: history, present status, and future directions. Ochsner J 2014; 14:596-607.

[5] Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. CIRCULATION 1999; 99:2993-3001.

[6] van Gelder BM, Bracke FA, Meijer A, Pijls NH. The hemodynamic effect of intrinsic conduction during left ventricular pacing as compared to biventricular pacing. J AM COLL CARDIOL 2005; 46:2305-10.

[7] Sweeney MO, Hellkamp AS, van Bommel RJ, Schalij MJ, Borleffs CJ, Bax JJ. QRS fusion complex analysis using wave interference to predict reverse remodeling during cardiac resynchronization therapy. HEART RHYTHM 2014; 11:806-13.

[8] Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. EUROPACE 1999; 1:126-30.
[9] Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. EUR J HEART FAIL 2001; 3:481-9.

[10] Choudhuri I, MacCarter D, Shaw R, Anderson S, St CJ, Niazi I. Clinical feasibility of exercise-based A-V interval optimization for cardiac resynchronization: a pilot study. Pacing Clin Electrophysiol 2014; 37:1499-1509.

[11] Bogaard MD, Meine M, Tuinenburg AE, Maskara B, Loh P, Doevendans PA. Cardiac resynchronization therapy beyond nominal settings: who needs individual programming of the atrioventricular and interventricular delay? EUROPACE 2012; 14:1746-53.

[12] Arbelo E, Tolosana JM, Trucco E, Penela D, Borras R, Doltra A, Andreu D, Acena M, Berruezo A, Sitges M, Mansour F, Castel A, Matas M, Brugada J, Mont L. Fusion-optimized intervals (FOI): a new method to achieve the narrowest QRS for optimization of the AV and VV intervals in patients undergoing cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2014; 25:283-92.

[13] Khaykin Y, Exner D, Birnie D, Sapp J, Aggarwal S, Sambelashvili A. Adjusting the timing of left-ventricular pacing using electrocardiogram and device electrograms. EUROPACE 2011; 13:1464-70.

[14] Jones RC, Svinarich T, Rubin A, Levin V, Phang R, Murillo J, Sambelashvili A. Optimal atrioventricular delay in CRT patients can be approximated using surface electrocardiography and device electrograms. J Cardiovasc Electrophysiol 2010; 21:1226-32.

[15] Hsing JM, Selzman KA, Leclercq C, Pires LA, McLaughlin MG, McRae SE, Peterson BJ, Zimetbaum PJ. Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy. Circ Arrhythm Electrophysiol 2011; 4:851-7.

[16] Linde C, Abraham WT, Gold MR, Daubert C. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVERses Remodeling in Systolic Left vEntricular Dysfunction) study. J AM COLL CARDIOL 2010; 56:1826-31.

[17] Tamborero D, Mont L, Sitges M, Silva E, Berruezo A, Vidal B, Delgado V, Tolosana JM, Godoy M, Castel A, Brugada J. Optimization of the interventricular delay in cardiac resynchronization therapy using the QRS width. AM J CARDIOL 2009; 104:1407-12.

[18] Tamborero D, Vidal B, Tolosana JM, Sitges M, Berruezo A, Silva E, Castel M, Matas M, Arbelo E, Rios J, Villacastin J, Brugada J, Mont L. Electrocardiographic versus echocardiographic optimization of the interventricular pacing delay in patients undergoing cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2011; 22:1129-34.
[19] Gold MR, Niazi I, Giudici M, Leman RB, Sturdivant JL, Kim MH, Yu Y, Ding J, Waggoner AD. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2007; 18:490-6.

[20] Sawhney NS, Waggoner AD, Garhwal S, Chawla MK, Osborn J, Faddis MN. Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. HEART RHYTHM 2004; 1:562-7.

**Figures**

**Figure 1**

Measurement of atrial activation and intrinsic atrioventricular conduction time Left panel: atrial activation time (Pend-As) and intrinsic atrioventricular conduction time (As-Vs) at the time of atrial sensing. Right panel: atrial activation time (Pend-Ap) and intrinsic atrioventricular conduction time (Ap-Vs) at the time of atrial pacing. AS: atrial sensing; AP: atrial pacing; VS: ventricular sensing.
**Figure 2**

Measurement of atrioventricular delay according to optimal ventricular resynchronization A representative electrocardiographic series shows measurement of pacing atrioventricular delay for optimal ventricular resynchronization. Ap-Vs=260 ms, pacing rate=90 bpm. The numbers shown on the top of the electrocardiograms are values (ms) of PAV. The narrowest QRS (128 ms) occurred at the PAV of 170 ms. Ap-Vs: the intrinsic atrioventricular conduction time at the time of atrial pacing. PAV: pacing AV delay.
Figure 3

The optimizing algorithm of the optimal AV delay Pend-As/ Pend-Ap: atrial activation time at atrial sensing/pacing; AV: atrioventricular; As-Vs/Ap-Vs: intrinsic atrioventricular conduction time at atrial sensing/pacing; SAVopt-AV/PAVopt-AV: sensing/pacing AV delay optimized according to optimal AV synchrony; SAVopt-V/PAVopt-V: sensing/pacing AV delay optimized according to optimal ventricular synchrony.
synchrony; D-values: different values; opt-SAV/opt-PAV: the optimal sensing/pacing AV delay with the maximal integrative AV and ventricular resynchronization.